Specifications
| SKU | ISG000381 |
| Brand | أفيروفاج |
| Categories | Medication & Treatments |
| Concentrations | 15/850 Mg |
| Shop by Concerns | High Blood Sugar |
| Gender | Neutral |
| Shop By Goals | Blood Glucose Control |
| Imported Or Local | Local |
| Ingredient | Metformin hydrochloride Pioglitazone |
| UPC | 6224008179399 |
| Product Form | Tablets |
| Specialty | Biguanide Combination Insulin Sensitizer Oral Anti-Diabetic |
| Sub Categories | Insulin And Diabetic Medicines |
| Unit Count | 30 Tablets |
| Warning | Avoid in severe renal impairment Monitor liver and kidney function Prescription only Use with Caution in Heart Failure Risk of Lactic Acidosis |
About the product›
Averofage 15/850 Mg 30 Tablets
Description:
Averofage 15/850 mg 30 tablets is an oral anti-diabetic prescription medicine combining pioglitazone and metformin for the management of type 2 diabetes mellitus in adults. It belongs to the class of insulin-sensitizing agents (thiazolidinediones) and biguanides, helping to improve blood glucose control when diet, exercise, and/or single-drug therapy are insufficient. This film-coated tablet is designed to reduce insulin resistance, decrease hepatic glucose production, and enhance peripheral glucose uptake, thereby supporting long-term glycemic control and reducing the risk of diabetes-related complications.
Indications:
- Type 2 diabetes mellitus (non–insulin-dependent diabetes mellitus) in adults, as an adjunct to diet and exercise.
- For patients insufficiently controlled on metformin alone or pioglitazone alone.
- For patients already receiving a combination of pioglitazone and metformin as separate tablets who may benefit from a fixed-dose combination for convenience and adherence.
- Helps reduce elevated fasting and postprandial blood glucose levels.
- Aims to improve overall glycemic control and support prevention of long-term microvascular and macrovascular complications associated with poorly controlled type 2 diabetes (such as neuropathy, nephropathy, and retinopathy), as part of a comprehensive diabetes management plan.
Active Ingredients / Key Components:
- Pioglitazone – 15 mg per tablet (thiazolidinedione class insulin sensitizer).
- Metformin hydrochloride – 850 mg per tablet (biguanide oral anti-diabetic).
- Excipients: film-coating and tablet core excipients (exact excipient list and concentrations , please check the product leaflet or the manufacturer’s official website; please refer to the official package insert for full details).
Dosage & Administration / How to Use:
- Averofage 15/850 mg must be used exactly as prescribed by a physician experienced in the management of diabetes.
- Usual dose: One tablet once or twice daily, or as directed by your doctor, depending on prior therapy and blood glucose response. Do not exceed the maximum daily dose prescribed by your healthcare provider.
- Take the tablet with meals to reduce gastrointestinal side effects related to metformin (such as nausea or abdominal discomfort).
- Swallow the tablet whole with a glass of water. Do not crush, break, or chew unless specifically advised by your doctor.
- Your doctor may adjust the dose gradually based on blood glucose monitoring, HbA1c levels, and tolerability.
- Continue to follow a controlled diet, regular physical activity, and weight management plan as recommended by your healthcare professional.
- If a dose is missed, take it as soon as you remember unless it is almost time for the next dose. Do not double the dose to make up for a missed tablet.
- Not recommended for use in children and adolescents; safety and efficacy in pediatric patients have not been established.
- Patients with renal or hepatic impairment, elderly patients, or those with heart failure require special dose consideration and close medical supervision.
Clinical Benefits:
- Improves insulin sensitivity: Pioglitazone enhances the body’s response to insulin in muscle and adipose tissue, helping cells use glucose more effectively.
- Reduces hepatic glucose production: Metformin suppresses excessive glucose output from the liver (decreased gluconeogenesis), lowering fasting blood glucose.
- Enhances peripheral glucose uptake and utilization: Metformin promotes peripheral glucose utilization, partly by increasing anaerobic glycolysis and facilitating glucose transporter activity.
- Helps control both fasting and postprandial blood sugar: The combination targets multiple pathophysiological defects in type 2 diabetes for more comprehensive glycemic control.
- May support weight neutrality or modest weight benefit compared with some other anti-diabetic agents, mainly due to metformin’s profile (individual results vary).
- Can improve lipid profile in type 2 diabetics: Metformin is known to have favorable effects on serum lipids in many patients, which may contribute to cardiovascular risk reduction as part of overall management.
- Convenient fixed-dose combination: Simplifies treatment regimen by combining two active ingredients in one tablet, which may enhance adherence and long-term control.
Warnings & Contraindications:
- Contraindicated in patients with known hypersensitivity to metformin, pioglitazone, or any component of the formulation.
- Contraindicated in patients with severe renal impairment or significant renal dysfunction due to the risk of lactic acidosis associated with metformin.
- Contraindicated in acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma.
- Use with caution in patients with hepatic impairment or a history of liver disease; liver function should be monitored periodically, particularly with pioglitazone.
- Pioglitazone may cause or exacerbate congestive heart failure; contraindicated in patients with NYHA Class III or IV heart failure and used with caution in those with cardiac history.
- May cause fluid retention and edema, especially when combined with insulin; monitor for signs of heart failure, rapid weight gain, or shortness of breath.
- Metformin is associated with a rare but serious risk of lactic acidosis, particularly in patients with renal impairment, dehydration, severe infection, shock, or conditions associated with hypoxia (e.g., heart failure, respiratory failure).
- Temporarily discontinue metformin-containing products before iodinated contrast imaging procedures and in situations of surgery or severe illness as advised by your doctor.
- Consult your doctor before use if pregnant, planning pregnancy, or breastfeeding. Insulin may be preferred in pregnancy; benefit-risk must be carefully evaluated.
- Consult your doctor before use if you have liver disease, kidney disease, heart disease, heart failure, dehydration, alcohol abuse, or are taking other anti-diabetic medicines, diuretics, or nephrotoxic drugs.
- Avoid excessive alcohol intake (acute or chronic) while taking metformin due to increased risk of lactic acidosis.
- Not intended for use in type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis.
- Monitor blood glucose regularly and follow your doctor’s instructions for dose adjustment.
- Keep out of reach of children.
- This product is a prescription medicine and must be used under medical supervision.
Side Effects:
- Common side effects: Gastrointestinal disturbances such as nausea, vomiting, abdominal pain, diarrhea, loss of appetite, or metallic taste (mainly related to metformin), usually mild and transient, often improving when taken with meals.
- Other possible side effects: Headache, dizziness, weight gain (more likely with pioglitazone), edema (swelling of legs or ankles), and upper respiratory tract infections.
- Hypoglycemia: More likely when used in combination with other anti-diabetic agents such as sulfonylureas or insulin. Symptoms include sweating, tremor, palpitations, hunger, confusion, or blurred vision.
- Serious but rare side effect: Lactic acidosis (associated with metformin) characterized by rapid breathing, severe weakness, muscle pain, abdominal discomfort, irregular heartbeat, or feeling very unwell. This is a medical emergency; stop the medicine and seek immediate medical attention.
- Pioglitazone-related risks: Fluid retention, exacerbation of heart failure, possible increased risk of bone fractures (especially in women), and rare liver function abnormalities. Report symptoms such as unexplained nausea, vomiting, abdominal pain, fatigue, dark urine, or jaundice.
- Vitamin B12 absorption may be reduced with long-term metformin therapy; periodic monitoring and supplementation may be required in some patients.
- If you experience severe, persistent, or unusual side effects, or signs of allergic reaction (rash, itching, swelling of face/tongue/throat, severe dizziness, difficulty breathing), stop the medication and contact your doctor immediately.
Storage Instructions:
Store in a cool, dry place away from direct sunlight. Keep container tightly closed. Keep out of reach of children.
Specifications:
- Product type: Prescription oral anti-diabetic medicine.
- Active ingredients: Pioglitazone 15 mg + Metformin hydrochloride 850 mg per film-coated tablet.
- Form: Film-coated tablet.
- Pack size: 30 tablets per pack.
- Intended use: Adult patients with type 2 diabetes mellitus as part of a comprehensive treatment plan including diet and exercise.
Disclaimer:
All pharmacy products are intended for general use only and do not replace professional medical advice, diagnosis, or treatment. Always consult a healthcare provider before use. Results may vary, and no specific outcomes are guaranteed. Products are not intended to diagnose, treat, cure, or prevent any disease unless stated. Follow label instructions carefully, as misuse may cause adverse effects. Compliance with local laws is the customer’s responsibility.
